CureVac Scores $296M In GlaxoSmithKline Partnership
Law360 (July 20, 2020, 4:28 PM EDT) -- GlaxoSmithKline will make a £234 million ($296 million) cash and equity investment in biotechnology company CureVac as they collaborate on up to five vaccines and antibodies targeting infectious diseases, the companies said Monday.
GlaxoSmithKline PLC will buy a roughly 10% stake in German drugmaker CureVac AG for £130 million and make an upfront cash payment of £104 million for research and development, the announcement said. CureVac's biotech platform focuses on developing and producing vaccines and therapeutics using messenger RNA, called mRNA, technology.
The partnership brings together complementary research and technology in the mRNA space, the companies' statement said.
"GSK fully recognizes...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!